Glenmede Trust’s Deciphera Pharmaceuticals, Inc. Common Stock DCPH Stock Holding History

Glenmede Trust’s Portfolio DCPH Stock Details DCPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-8,171	Closed	-$366K	–	1324
2021 Q1	$366K	Buy	8,171 +117	+1%	+$5.45K	﹤0.01%	928
2020 Q4	$459K	Buy	8,054 +815	+11%	+$48.3K	﹤0.01%	861
2020 Q3	$371K	Buy	7,239 +1,815	+33%	+$88.9K	﹤0.01%	870
2020 Q2	$323K	Buy	5,424 +1,175	+28%	+$62.9K	﹤0.01%	884
2020 Q1	$264K	Hold	4,249	–	–	﹤0.01%	1093
2019 Q4	$264K	Buy	4,249 +199	+5%	+$9.46K	﹤0.01%	1093
2019 Q3	$137	Buy	+4,050	New	+$120K	﹤0.01%	1294

Other funds holding DCPH

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Glenmede Trust's DCPH Position: Q2 2021 in Review

Glenmede Trust sold out of Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) in Q2 2021, closing a stake of 8,171 shares — an estimated $366K sold.

Glenmede Trust first reported a position in DCPH in Q3 2019 and held it in 7 quarters. The position peaked at $459K in Q4 2020. 147 funds tracked by Wall St. Rank hold DCPH as of Q2 2021.

Glenmede Trust reported no remaining Deciphera Pharmaceuticals, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
Glenmede Trust sold 8,171 Deciphera Pharmaceuticals, Inc. Common Stock shares in Q2 2021, an estimated $366K.
Glenmede Trust first reported a position in Deciphera Pharmaceuticals, Inc. Common Stock in Q3 2019 and held it in 7 quarters.
Glenmede Trust's Deciphera Pharmaceuticals, Inc. Common Stock position peaked at $459K in Q4 2020.
147 funds tracked by Wall St. Rank held Deciphera Pharmaceuticals, Inc. Common Stock as of Q2 2021.

Based on Glenmede Trust's 13F filing for Q2 2021, filed 16 Aug 2021.